{"product_id":"adipotide-30-mg-pen","title":"Adipotide | 30 mg pen","description":"\u003cp class=\"p1\"\u003eAdipotide (FTPP) is a synthetic peptidomimetic studied for its role in adipose-tissue modulation through vascular-targeting mechanisms. In preclinical research, it has been evaluated in models where fat-mass reduction, adipose vascular regression, and metabolic marker changes are measured as endpoints. Information on this page is provided for scientific and educational context only and does not represent medical guidance or therapeutic claims.\u003c\/p\u003e\n\u003cp class=\"p1\"\u003e\u003cstrong\u003eSupports\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp class=\"p1\"\u003eAdipose tissue targeting assessed via vascular receptor-mediated binding mechanisms.\u003cbr\u003eFat-mass reduction endpoints tracked through adipose-specific vascular disruption models.\u003cbr\u003eBody-composition changes evaluated in controlled obesity and metabolic research frameworks.\u003cbr\u003eMetabolic marker shifts measured through insulin-sensitivity and lipid-profile endpoints.\u003cbr\u003eAdipocyte viability and apoptosis signaling assessed in tissue-specific experimental models.\u003c\/p\u003e\n\u003cp class=\"p1\"\u003e\u003cstrong\u003eDESCRIPTION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp class=\"p1\"\u003eAdipotide is a synthetic peptide originally developed as a vascular-targeting compound for white adipose tissue. In experimental biology, it is studied for its ability to selectively bind to receptors expressed on blood vessels supplying fat tissue, leading to downstream vascular disruption and secondary adipocyte loss in controlled models.\u003c\/p\u003e\n\u003cp class=\"p1\"\u003eMechanistic literature commonly describes Adipotide as a chimeric construct combining a targeting sequence associated with adipose vasculature and a pro-apoptotic domain. This design enables selective localization to fat-associated endothelial cells, where mitochondrial disruption and apoptosis signaling have been observed in laboratory settings. Unlike endocrine-based metabolic compounds, Adipotide is studied as a structural and vascular modulator of adipose tissue.\u003c\/p\u003e\n\u003cp class=\"p1\"\u003eAdipotide is presented here for controlled research and educational context only. It is not marketed as a therapeutic intervention, and observed outcomes vary by model, protocol, and experimental design.\u003c\/p\u003e\n\u003cp class=\"p1\"\u003e\u003cstrong\u003eCLINICAL STATUS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp class=\"p1\"\u003eAdipotide has published preclinical research across multiple models, including rodent and non-human primate obesity studies. Observations have included reductions in body weight and fat mass under controlled conditions, alongside monitored safety endpoints. It is not approved for general human therapeutic use and remains an experimental research compound.\u003c\/p\u003e\n\u003cp class=\"p1\"\u003e\u003cstrong\u003eEvidence type:\u003c\/strong\u003e\u003cbr\u003eHuman RCT ✘ | Observational ✘ | Animal ✔ | Non-human primate ✔ | In vitro ✔ | Regulatory approval ✘\u003c\/p\u003e\n\u003cp class=\"p1\"\u003e\u003cstrong\u003eMECHANISM OF ACTION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp class=\"p1\"\u003eMechanistic models of Adipotide emphasize targeted binding to receptors associated with white adipose tissue vasculature. Following binding and internalization, the peptide’s pro-apoptotic domain has been shown to disrupt mitochondrial integrity in endothelial cells, leading to apoptosis of the vascular structures supplying fat tissue.\u003c\/p\u003e\n\u003cp class=\"p1\"\u003eIn applied research contexts, this vascular disruption results in reduced nutrient and oxygen delivery to adipocytes, contributing to adipocyte stress and subsequent fat-mass reduction. These effects are typically measured through imaging, body-weight changes, and metabolic marker panels. Unlike GLP-1 or appetite-regulating compounds, Adipotide does not primarily act through central nervous system pathways.\u003c\/p\u003e\n\u003cp class=\"p1\"\u003e\u003cstrong\u003eBENEFITS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp class=\"p1\"\u003e\u003cstrong\u003eTargeted Adipose Tissue Modulation:\u003c\/strong\u003e\u003cbr\u003eAdipotide has been studied for its ability to selectively target fat-associated vasculature. In experimental models, this targeted approach has resulted in localized reductions in adipose tissue without broad systemic stimulation.\u003c\/p\u003e\n\u003cp class=\"p1\"\u003e\u003cstrong\u003eFat Mass Reduction In Preclinical Models:\u003c\/strong\u003e\u003cbr\u003eAnimal studies, including primate research, have reported measurable decreases in fat mass and body weight under defined dosing protocols. These outcomes are linked to vascular disruption and adipocyte loss.\u003c\/p\u003e\n\u003cp class=\"p1\"\u003e\u003cstrong\u003eNon-Endocrine Mechanism:\u003c\/strong\u003e\u003cbr\u003eAdipotide operates independently of hormonal pathways such as GLP-1 or leptin signaling. This allows it to be studied in models where appetite-independent fat modulation is investigated.\u003c\/p\u003e\n\u003cp class=\"p1\"\u003e\u003cstrong\u003eMetabolic Marker Improvements:\u003c\/strong\u003e\u003cbr\u003eResearch has documented changes in lipid profiles and insulin-related markers following treatment in controlled models. These effects are considered downstream of adipose tissue reduction.\u003c\/p\u003e\n\u003cp class=\"p1\"\u003e\u003cstrong\u003eVascular Targeting Strategy:\u003c\/strong\u003e\u003cbr\u003eThe peptide’s design supports receptor-mediated targeting of adipose tissue blood vessels. This selective mechanism is central to its experimental profile.\u003c\/p\u003e\n\u003cp class=\"p1\"\u003e\u003cstrong\u003eBody Composition Research Applications:\u003c\/strong\u003e\u003cbr\u003eAdipotide is frequently used in research frameworks focused on body composition, fat distribution, and metabolic health under controlled conditions.\u003c\/p\u003e\n\u003cp class=\"p1\"\u003e\u003cstrong\u003eRESEARCH DATA\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp class=\"p1\"\u003eStudy\/model | Reported effect\u003cbr\u003eObese primate model (preclinical) | Reduction in fat mass and body weight with monitored metabolic changes.\u003cbr\u003eRodent obesity model | Demonstrated adipose tissue loss via vascular-targeting mechanisms.\u003cbr\u003eEndothelial-cell mechanistic studies | Observed mitochondrial disruption and apoptosis signaling in targeted cells.\u003cbr\u003eMetabolic profiling studies | Reported changes in lipid and insulin-related markers following treatment.\u003c\/p\u003e\n\u003cp class=\"p1\"\u003e\u003cstrong\u003eSTACK SUGGESTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp class=\"p1\"\u003eIn experimental metabolic-design contexts, Adipotide is sometimes paired with:\u003c\/p\u003e\n\u003cp class=\"p1\"\u003eGLP-1 analogues (appetite-regulation comparison frameworks)\u003cbr\u003eNAD+ (bioenergetic and metabolic marker studies)\u003cbr\u003eL-Carnitine (lipid metabolism and oxidation research models)\u003c\/p\u003e\n\u003cp class=\"p1\"\u003eStacks discussed are for experimental design only, not safety or efficacy guidance.\u003c\/p\u003e\n\u003cp class=\"p1\"\u003e\u003cstrong\u003ePOSSIBLE SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp class=\"p1\"\u003eIn preclinical and observational research settings, the following have been reported:\u003c\/p\u003e\n\u003cp class=\"p1\"\u003eFatigue or reduced energy in active tissue-modulation phases.\u003cbr\u003eInjection-site reactions including redness or discomfort.\u003cbr\u003eTransient metabolic adjustments depending on protocol design.\u003cbr\u003ePotential systemic stress responses under higher exposure models.\u003c\/p\u003e\n\u003cp class=\"p1\"\u003eThis section is provided for general context only and does not constitute medical guidance.\u003c\/p\u003e\n\u003cp class=\"p1\"\u003e\u003cstrong\u003eSCIENTIFIC REFERENCES\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp class=\"p1\"\u003eAdipotide studies in obese primate models — Preclinical research\u003cbr\u003eMechanistic studies on adipose vascular targeting peptides\u003cbr\u003eMitochondrial disruption in endothelial cells — Experimental data\u003cbr\u003eObesity model interventions using targeted peptides — Translational research\u003c\/p\u003e\n\u003cp class=\"p1\"\u003e\u003cstrong\u003eCAUTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp class=\"p1\"\u003eFor educational and scientific context only; not intended to diagnose, treat, cure, or prevent any disease.\u003cbr\u003eNot approved for general medical use.\u003cbr\u003eOutcomes vary based on experimental design and model conditions.\u003cbr\u003eConsult a qualified professional for any health-related decisions.\u003c\/p\u003e","brand":"Peptoora","offers":[{"title":"Default Title","offer_id":61699717726538,"sku":null,"price":429.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0887\/1139\/7706\/files\/Adipotide.png?v=1777101877","url":"https:\/\/peptoora.com\/es\/products\/adipotide-30-mg-pen","provider":"Peptoora LTD","version":"1.0","type":"link"}